DATIRIUM LLC
Cincinnati, OH · Biotech · Private
SciDAP, a multi-omics data analysis platform with containerized bioinformatics pipelines and user-friendly graphical interface for NGS analysis
- Grants
- $4.6M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Commercialization of SciDAP, a next generation universal platform for collaborative data analysis | $426,500 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · SciDAP: a next generation universal platform for collaborative data analysis | $374,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Commercialization of SciDAP, a next generation universal platform for collaborative data analysis | $52,000 | |
| Federal grant | Department of Health and Human Services · Phase II · SciDAP: Scientific Data Analysis Platform | $802,500 | |
| Federal grant | Department of Health and Human Services · Phase II · SciDAP: Scientific Data Analysis Platform | $1,582,124 | |
| Federal grant | Department of Health and Human Services · Phase II · SciDAP: Scientific Data Analysis Platform | $779,624 | |
| Federal grant | Department of Health and Human Services · Phase I · Bioinformatics pipeline for personalized diagnostics of transplant rejection | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Bioinformatics pipeline for personalized diagnostics of transplant rejection | $306,500 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3338 | Timberlyne Therapeutics | — | — |
| 3339 | POP Biotechnologies Inc. | — | — |
| 3340 | SiMPore, Inc. | — | $1.0M |
| 3341 | DATIRIUM LLC | — | — |
| 3342 | Stealth Biosciences, Inc | — | — |
| 3343 | SOMATOLYNK, INC. | — | — |
| 3344 | WILLIAM D SHANNON CONSULTING LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.